Fatty acid conjugates
eMolecules 30414-55-2 | ChemScene | 5-Methyl-3-oxohexanoic acid methyl ester | 1g | 536840621 | CS-W000361 | MFCD12031307 | 158.197 | C8H14O3
ChemScene | 4-(24-Difluorophenoxy)benzoic acid | 100mg | 572188238 | CS-0095163 | 748183-47-3 | MFCD11529198 | 250.201 | C13H8F2O3
If you are unable to find the chemical you are looking for, make sure you are logged into your fishersci.com account and click on the following link:
eMolecules Building Block Tool<|a>
Medchemexpress LLC Ro-5963 | 1416663-77-8 | 98.2% | 50 MG
RO-5963 is a small-molecule dual inhibitor of p53-MDM2 and p53-MDMX that activates the p53 pathway and induces apoptosis in cancer cell lines. It exhibits nanomolar potency and has demonstrated increased apoptotic activity compared with Nutlin in MCF7 and ZR75-30 cells.
- Dual p53-MDM2 and p53-MDMX inhibition (IC50 ≈ 17 nM and 24 nM)
- High in vitro potency and apoptosis induction in breast cancer cell lines
- Soluble in DMSO at 150 mg/mL for in vitro use
- Available as solids in multiple milligram sizes and as DMSO solutions
- Recommended storage: powder -20°C (3 years) or 4°C (2 years); in solvent -80°C (6 months)
Medchemexpress LLC MBQ-167 | 2097938-73-1 | 99.9% | 338.41 | 1 ML
MBQ-167 is a dual Rac/Cdc42 inhibitor. It has IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells. It is for research use only and not sold to patients.
- Induces loss of polarity in metastatic breast cancer cells at concentrations ≥100 nM.
- Treatment with 500 nM for 24 hours results in ~95% cell rounding and detachment in MDA-MB-231 cells.
- Active in various mesenchymal cancer cell types including breast, pancreatic, ovarian, gastric, and neuroblastoma cells.
- Reduces Rac activation in MDA-MB-231 cells.
- In vivo, significantly reduces tumor growth in mice (~80% reduction at 1.0 mg/kg BW and ~95% reduction at 10 mg/kg BW).
- 10X more effective than EHop-016 in reducing tumor growth in mice.
Medchemexpress LLC Mbq-167 | 2097938-73-1 | 99.9% | 338.41 | 100 MG
MBQ-167 is a dual Rac/Cdc42 inhibitor, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells. It is for research use only.
- Dual Rac/Cdc42 inhibitor.
- Available in solid and solution forms.
- Significantly reduces migration of liver specific Dnmt3a-/- hematopoietic cells at 200 nM (20 h).
- Induces a loss of polarity in metastatic breast cancer cells at concentrations ≥100 nM.
- Causes ~95% cell rounding and detachment in metastatic MDA-MB-231 cells at 500 nM for 24 h.
- Inhibits Rac activity in attached and detached cancer cells.
- Induces phenotype in various mesenchymal cancer cell types.
- Demonstrates a statistically significant reduction in tumor growth in treated mice, with an ~80% reduction at 1.0 mg/kg BW and ~95% reduction at 10 mg/kg BW.
- 10 times more effective than EHop-016 in reducing tumor growth in mice.